Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06183983 | Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma(MOSAIC) | recruiting | N/A | 53 | Erasmus Medical CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07014943 | High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 34 | Sichuan UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06551909 | Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2) | recruiting | N/A | 30 | IRCCS San RaffaeleOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06818331 | Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial | recruiting | Phase 2 | 20 | The Third Affiliated hospital of Zhejiang Chinese Medical UniversityOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05036564 | Diagnosis; Objective RespOnse; THErApy(DOROTHEA) | recruiting | N/A | 70 | IRCCS San RaffaeleOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT05439278 | Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma | recruiting | Phase 3 | 178 | Severance HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT05380349 | Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma | recruiting | Early Phase 1 | 10 | Swedish Medical CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05474573 | Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases(CONFLUENSE) | recruiting | N/A | 52 | Sklifosovsky Institute of Emergency CareOTHER_GOV | 1 | May 16, 2025 | clinicaltrials |
| NCT06975332 | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression | recruiting | N/A | 35 | Medical University of WarsawOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06381570 | Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas(VICTORY) | recruiting | Early Phase 1 | 57 | Daniel MorgensternOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04254419 | Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells | recruiting | Phase 1 | 18 | Nationwide Children's HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06598787 | A Study of BL-B01D1 in Patients With Recurrent Glioblastoma | recruiting | Phase 2 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06946407 | Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma | recruiting | N/A | 41 | FengYan JinOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05432518 | Pilot Trial for Treatment of Recurrent Glioblastoma | recruiting | Early Phase 1 | 10 | AHS Cancer Control AlbertaOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04737889 | Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06874426 | The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction(Endo-Olfact) | recruiting | — | 154 | Universitaire Ziekenhuizen KU LeuvenOTHER | 3 | Apr 23, 2025 | clinicaltrials |
| NCT06936046 | Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression | recruiting | Phase 2 | 200 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT04997317 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide(PROMENADE) | recruiting | Phase 1 / Phase 2 | 18 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04250064 | A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma(LoBULarDIPG) | recruiting | Phase 2 | 40 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06016452 | A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma(CHROME) | recruiting | Phase 2 | 118 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06779487 | Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline(BIO-RIN) | recruiting | — | 200 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06924099 | TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)(TIGER France) | recruiting | — | 430 | NovoCure Ltd.INDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1) | recruiting | Phase 2 | 141 | Day One Biopharmaceuticals, Inc.INDUSTRY | 11 | Apr 10, 2025 | clinicaltrials |
| NCT04474964 | Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.(FOR-WNT2) | recruiting | N/A | 30 | Tata Memorial CentreOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06036381 | Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis(GLIO-RAD) | recruiting | — | 1,000 | Tata Memorial CentreOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06687681 | Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas | recruiting | Phase 2 | 40 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06915649 | Exploration and Evaluation of Amygdalo-Hippocampectomy According to Prof. Coubes' Technique: An Anatomical, Clinical, and Educational Approach | recruiting | — | 3,504 | University Hospital, MontpellierOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04025541 | Analysis of Circulating Tumor Markers in Blood(ALCINA2) | recruiting | N/A | 992 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06801756 | Craniopharyngioma and Pregnancies(CRANIOGESTE) | recruiting | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03849430 | Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients(Glioma2015) | recruiting | — | 750 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05460507 | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | recruiting | Phase 1 | 40 | Plus TherapeuticsINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06221553 | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG(CMD03DIPG) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT01906385 | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | recruiting | Phase 1 / Phase 2 | 55 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05793034 | Predictive Factors for Survival in Aggressive Meningiomas(23Men) | recruiting | N/A | 250 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05941234 | Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma(IPerGlioGEM) | recruiting | N/A | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05274919 | Vascular Signature Mapping of Brain Tumor Genotypes(VASIM) | recruiting | — | 180 | Leiden University Medical CenterOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05769660 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) | recruiting | Phase 1 | 12 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05565326 | Response Assessment During MR-guided Radiation Therapy for Glioblastoma(MARGA) | recruiting | — | 20 | University of ZurichOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05231655 | Ex VIvo DEtermiNed Cancer Therapy(EVIDENT) | recruiting | — | 600 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06831773 | Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma | recruiting | N/A | 23 | Gansu Wuwei Tumor HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06832267 | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | recruiting | N/A | 44 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06832384 | Intensive Physiotherapy in Children Affected by Posterior Fossa Tumors | recruiting | — | 40 | IRCCS Eugenio MedeaOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06000787 | MCT for the Harvard/UCSF ROBIN Center | recruiting | N/A | 47 | Brigham and Women's HospitalOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06830356 | Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas.(SPIDER-MEN) | recruiting | N/A | 53 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06830421 | Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients(PRIMA-CNS) | recruiting | Phase 3 | 340 | University Hospital FreiburgOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06140875 | Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF) | recruiting | N/A | 26 | Charite University, Berlin, GermanyOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06113705 | Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study. | recruiting | N/A | 75 | Istituto Clinico HumanitasOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 12, 2025source: clinicaltrials